Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
Articolo
Data di Pubblicazione:
2021
Citazione:
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study / Barbanti, Piero; Aurilia, Cinzia; Cevoli, Sabina; Egeo, Gabriella; Fofi, Luisa; Messina, Roberta; Salerno, Antonio; Torelli, Paola; Albanese, Maria; Carnevale, Antonio; Bono, Francesco; D'Amico, Domenico; Filippi, Massimo; Altamura, Claudia; Vernieri, Fabrizio. - In: HEADACHE. - ISSN 0017-8748. - 6:(2021), pp. 1351-1363. [10.1111/head.14194]
Abstract:
To evaluate the long-term effectiveness, safety, and tolerability of erenumab in a real-world migraine population, looking for putative predictors of responsiveness.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
allodynia; calcitonin gene-related peptide; erenumab; long-term treatment; migraine; sex
Elenco autori:
Barbanti, Piero; Aurilia, Cinzia; Cevoli, Sabina; Egeo, Gabriella; Fofi, Luisa; Messina, Roberta; Salerno, Antonio; Torelli, Paola; Albanese, Maria; Carnevale, Antonio; Bono, Francesco; D'Amico, Domenico; Filippi, Massimo; Altamura, Claudia; Vernieri, Fabrizio
Link alla scheda completa:
Pubblicato in: